Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2001

View Archived Issues

Novartis highlights significant events during first half of 2001

Long-term outcome in patients with severe PH receiving continuous s.c. UT-15

Oxovanadium compound shows promising activity against tumor growth and metastasis

Piperidine urea-based compounds selective for human beta3-adrenoceptors

Advance in the design of anticancer G-quadruplex ligands reported at ACS meeting

Selective inhibitors of human iNOS: SAR in a series of 2-iminopyrrolidine amino acids

Xefo introduced by CeNeS in U.K.

Pariet receives E.U. clearance for treatment of symptomatic GERD

Major European launch announced for new CLL therapy

Cialis NDA accepted for FDA review

GeneData and diaDexus establish functional genomic data analysis collaboration

Emerging pharmaceutical company announces name change

Synthetic SOD/catalase mimetic may prove useful in sideroblastic anemia

Important new information on heart failure now available from Prous Science

Pharmacyclics reports interim phase I results for Antrin photoangioplasty for CAD

Potential of darusentan in CHF, hypertension supported by clinical trial results

Positive preliminary phase II data reported for Stressgen's HspE7

Z-350 may reduce prostate growth without other hormonal effects

Pfizer NK1 antagonists particularly useful in neovascularization-associated conditions

Modulators of delta opioid receptors and potential uses thereof described by Ortho-McNeil

SCRAS patents new series of somatostatin receptor ligands

Recent patent covers new oxazolidinone antibacterials discovered at Pharmacia

NK1 antagonist HSP-117 active in purported rat model of emesis -- cisplatin-induced pica

Selective inhibitors of nNOS claimed by AstraZeneca for CNS disorders

Byk Gulden presents new alkynyl tryptase inhibitors

AltaRex completes primary analysis of OvaRex clinical trial

Org-30659 comparable to desogestrel for effects on ovarian function

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...